Antitumor effects of atorvastatin in the chemoprevention of rat mammary carcinogenesis

Biologia

Volumn 66, Issue 4, 2011, Pages 727-734

  Kubatka, Peter ^a,b   Žihlavniková, Katarína ^a   Solár, Peter ^c   Kajo, Karol ^a,d   Valentová, Vanda ^a   Péč, Martin ^a,b   Bojková, Bianka ^c   Kassayová, Monika ^c   Stollárová, Nadežda ^b   Ahlers, Ivan ^c  

^a University Teaching Hospital in Martin   (Slovakia)

^b CATHOLIC UNIVERSITY IN RU OMBEROK   (Slovakia)

^c P J AFÁRIK UNIVERSITY   (Slovakia)

^d Diagnostic Centre Ltd   (Slovakia)

Author keywords

apoptosis; atorvastatin; chemoprevention; mammary carcinogenesis; rat

Indexed keywords

RATTUS;

EID: 79958292875     PISSN: 00063088     EISSN: 13369563     Source Type: Journal    
DOI: 10.2478/s11756-011-0077-3     Document Type: Article

References (47)

1. Aprigliano I., Dudas J., Ramadori G. & Saile B. 2008. Atorvastatin induces apoptosis by a caspase-9 dependent pathway: an in vitro study on activated rat hepatic stellate cells. Liver Int. 28: 546-557.
2. Blais L., Desgagne A. & Lelorier J. 2000. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch. Int. Med. 160: 2363-2368.
3. Blanco-Colio L. M., Villa A., Ortego M., Hernández-Presa M. A., Pascual A., Plaza J. J. & Egido J. 2002. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by down regulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 161: 17-26.
4. Bonovas S., Filioussi K. & Sitaras N. M. 2008. Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. Int. J. Cancer 123: 899-904.
5. Boudreau D. M., Yu O. & Johnson J. 2010. Statin use and cancer risk: a comprehensive review. Expert Opin. Drug Saf. 9: 603-621.
6. Cafforio P., Dammacco F., Gernone A. & Silvestris F. 2005. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26: 883-891.
7. Cauley J. A., Zmuda J. M., Lui L. Y., Hillier T. A., Ness R. B., Stone K. L., Cummings S. R. & Douglas D. C. 2003. Lipid-lowering drug use and breast cancer in older women: a prospective study. J. Women Health 12: 749-756.
8. Chamilová M., Bojková B., Kubatka P., Kalická K., Adámeková E., Ahlers I. & Ahlersová E. 2001. Prevention of N-methyl-Nnitrosourea-induced mammary carcinogenesis in female rats by tamoxifen and melatonin: metabolic alterations. Biologia 56: 565-571.
9. Collisson E. A., Kleer C., Wu M., De A., Gambhir S. S., Merajver S. D. & Colodney M. S. 2003. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol. Cancer Ther. 2: 941-948.
10. Denoyelle C., Vasse M., Korner M., Mishal Z., Ganné F., Vannier J. P., Soria J. & Soria C. 2001. Cerivastatin, an inhibitor of HMGCoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22: 1139-1148.
11. Downs J. R., Clearfield M., Weis S., Whitney E., Shapiro D. R., Beere P. A., Langendorfer A., Evan A., Stein E. A., Kruyer W. & Gotto A. M. Jr. 1998. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615-1622.
12. Eaton M., Eklof J., Beal J. R. & Sahmoun A. E. 2009. Statins and breast cancer in postmenopausal women without hormone therapy. Anticancer Res. 29: 5143-5148.
13. Fagherazzi G., Fabre A., Boutron-Ruault M. C. & Clavel-Chapelon F. 2010. Serum cholesterol level, use of a cholesterollowering drug, and breast cancer: results from the prospective E3N cohort. Eur. J. Cancer Prev. 19: 120-125.
14. Garwood E. R., Kumar A. S., Baehner F. L., Moore D. H., Au A., Hylton N., Flowers C. I., Garber J., Lesnikoski B. A., Hwang E. S., Olopade O., Port E. R., Campbell M. & Esserman L. J. 2010. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res. Treat. 119: 137-144.
15. Hawk M. A., Cesen K. T., Siglin J. C., Stoner G. D. & Ruch R. J. 1996. Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. Cancer Lett. 109: 217-222.
16. Hindler K., Cleeland CH. S., Rivera E. & Collard CH. D. 2006. The role of statins in cancer therapy. Oncologist 11: 306-315.
17. Inano H., Suzuki K., Onoda M. & Wakabayashi K. 1997. Anticarcinogenic activity of simvastatin during the promotion phase of radiation-induced mammary tumorigenesis of rats. Carcinogenesis 18: 1723-1727.
18. Jiang Z., Zheng X., Lytle R. A., Higashikubo R. & Rich K. M. 2004. Lovastatin-induced up-regulation of the BH3-only protein, Bim, and cell death in glioblastoma cells. J. Neurochem. 89: 168-178.
19. Kamat A. M. & Nelkin G. M. 2005. Atorvastatin: a potential chemopreventive agent in bladder cancer. Urology 66: 1209-1212.
20. Katz M. S., Minsky B. D., Saltz L. B., Riedel. E., Chessin D. B. & Guillem J. G. 2005. Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 62: 1363-1370.
21. Kawata S., Yamasaki E., Nagase T., Inui Y., Ito N., Matsuda Y., Inada M., Tamura S., Noda S., Imai Y. & Matsuzawa Y. 2001. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br. J. Cancer 84: 886-891.
22. Khurana V., Bejjanki H. R., Caldito G. & Owens M. W. 2007. Statins reduce the risk of lung cancer in humans: a large casecontrol study of US veterans. Chest 131: 1282-1288.
23. Kikuchi T., Nagata Y. & Abe T. 1997. In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells. J. Neurooncol. 34: 233-239.
24. Kubatka P., Ahlersová E., Ahlers I., Marková M., Bojková B., Kalická K. & Adámeková E. 2002. Raloxifene and melatonin in the prevention of 7, 12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in female rats. Biologia 57: 627-634.
25. Kubatka P., Žihlavnikova K., Kajo K., Peč M., Stollarova N., Bojkova B., Kassayova M. & Orendaš P. 2011. Antineoplastic effects of simvastatin in experimental breast cancer. Klin. Onkol. 24: 41-45.
26. Kusama T., Mukai M., Iwasaki T., Tatsuta M., Matsumoto Y., Akedo H., Inoue M. & Nakamura H. 2002. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 122: 308-317.
27. Lubet R. A., Boring D., Steele V. E., Ruppert J. M., Juliana M. M. & Grubbs C. J. 2009. Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis. Cancer Prev. Res. 2: 161-167.
28. MacDonald J. S., Gerson R. J., Kornbrust D. J., Kloss M. W., Prahalada S., Berry P. H., Alberts A. W. & Bokelman D. L. 1988. Preclinical evaluation of lovastatin. Am. J. Cardiol. 62: 16J-27J.
29. Matar P., Rozados V. R., Roggero E. A. & Scharovsky O. G. 1998. Lovastatin inhibits tumor growth and metastasis development of a rat fibrosarcoma. Cancer Biother. Radiopharm. 13: 387-393.
30. Minden M. D., Dimitroulakos J., Nohynek D. & Penn L. Z. 2001. Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia. Leuk. Lymphoma 40: 659-662.
31. Narisawa T., Fukaura Y., Terada K., Umezawa A., Tanida N., Yazawa K. & Ishikawa CH. 1994. Prevention of 1, 2-dimethylhydrazine-induced colon tumorigenesis by HMGCoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. Carcinogenesis 15: 2045-2048.
32. Narisawa T., Morotomi M., Fukaura Y., Hasebe M., Ito M. & Aizawa R. 1996. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn. J. Cancer Res. 87: 798-804.
33. Nubel T., Dippold W., Kleinert H., Kaina B. & Fritz G. 2004. Lovastatin inhibits Rho-regulated expression of E-selectin by TNFα and attenuates tumor cell adhesion. FASEB J. 18: 140-142.
34. Park H. J., Kong D., Iruela-Arispe L., Begley U., Tang D. & Galper J. B. 2002. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ. Res. 91: 143-150.
35. Poynter J. N., Gruber S. B., Higgins P. D., Almog R., Bonner J. D., Rennert H. S., Low M., Greenson J. K. & Rennert G. 2005. Statins and the risk of colorectal cancer. N. Engl. J. Med. 352: 2184-2192.
36. Rao S., Lowe M., Herliczek T. W. & Keyomars K. 1998. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of DK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 17: 2393-2402.
37. Robison R. L., Suter W. & Cox R. H. 1994. Carcinogenicity and mutagenicity studies with fluvastatin, a new, entirely synthetic HMG-CoA reductase inhibitor. Fundam. Appl. Toxicol. 23: 9-20.
38. Russo J. & Russo I. H. 2000. Atlas and histologic classification of tumors of the rat mammary gland. J. Mammary Gland Biol. Neoplasia 5: 187-200.
39. Shannon J., Tewoderos S., Garzotto M., Beer T. M., Derenick R., Palma A. & Farris P. E. 2005. Statins and prostate cancer risk: a case-control study. Am. J. Epidemiol. 162: 318-325.
40. Smith P. F., Grossman S. J., Gerson R. J., Gordon L. R., Deluca J. G., Majka J. A., Wang R. W., Germershausen J. I. & Mac-Donald J. S. 1991. Studies on the mechanism of simvastatininduced thyroid hypertrophy and follicular cell adenoma in the rat. Toxicol. Pathol. 19: 197-205.
41. Tatsuta M., Iishi H., Baba M., Iseki K., Yano H., Uehara H., Yamamoto R. & Nakaizumi A. 1998. Suppression by pravastatin, an inhibitor of p21ras isoprenylation, of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats. Br. J. Cancer 77: 581-587.
42. Wang I. K., Lin-Shiau S. Y. & Lin J. K. 2000. Induction of apoptosis by lovastatin through activation of caspase-3 and DNase II in leukaemia HL-60 cells. Pharmacol. Toxicol. 86: 83-91.
43. Weis M., Heeschen C., Glassford A. J. & Cooke J. P. 2002. Statins have biphasic effects on angiogenesis. Circulation 105: 739-745.
44. Woditschka S., Habel L. A., Udaltsova N., Friedman G. D. & Sieh W. 2010. Lipophilic statin use and risk of breast cancer subtypes. Cancer Epidemiol. Biomark. Prev. 19: 2479-2487.
45. Xiao H., Zhang Q., Lin Y., Reddy B. S. & Yang CH. H. 2008: Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int. J. Cancer 122: 2115-2124.
46. Yang Y. X., Hennessy S., Propert K., Hwang W. T., Sarkar M. & Lewis JD. 2008. Chronic statin therapy and the risk of colorectal cancer. Pharmacoepidemiol. Drug Saf. 17: 869-876.
47. Yu O., Boudreau D. M., Buist D. S. & Miglioretti D. L. 2009. Statin use and female reproductive organ cancer risk in a large population-based setting. Cancer Causes Control 20: 609-616.